Cargando…

PB2022: ELTROMBOPAG IN MYELODYSPLASTIC SYNDROME AND CHRONIC MYELOMONOCYTIC LEUKEMIA: A SINGLE-CENTER EXPERIENCE

Detalles Bibliográficos
Autores principales:	Peña, Amaia Lopez, Miguelez, Marta Sofia Ordas, Lefler, Carmen Rodriguez, Gomez, Pablo Estuardo Lopez, Gutierrez, Mar Herrero, Cuezva, Laura Fernandez, Membreño, Jhossyuriel Obregon, Resina, Rita Gonzalez, Martínez, Laura Villarroya, Bahillo, Leire Etxebarria, Gil, Rafael Monleon, Molias, Ana Cristina Godoy, Morfa, Miguel Diaz, Garcia, Isabel Izquierdo, Beltran, Pilar Delgado, Navarro, Gonzalo Caballero
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430309/ http://dx.doi.org/10.1097/01.HS9.0000974896.21144.86

Ejemplares similares

PB2215: HYDROXYUREA-INDUCED CUTANEUS ADVERSE EVENTS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: A SINGLE-CENTER EXPERIENCE
por: Peña, Amaia Lopez, et al.
Publicado: (2023)

Preclinical evaluation of eltrombopag in a PDX model of myelodysplastic syndromes
por: Schmitt, Nanni, et al.
Publicado: (2021)

Spliceosome mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Chesnais, Virginie, et al.
Publicado: (2012)

Decitabine/cedazuridine for chronic myelomonocytic leukaemia, myelodysplastic syndromes
Publicado: (2022)

Evolution of chronic myelomonocytic leukemia from refractory anemia: the unusual course of a myelodysplastic syndrome
por: Niscola, Pasquale, et al.
Publicado: (2013)

Age-related diseases of inflammation in myelodysplastic syndrome and chronic myelomonocytic leukemia
por: Weeks, Lachelle D., et al.
Publicado: (2022)

Decitabine/Cedazuridine in the Management of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia in Canada
por: Yun, John Paul, et al.
Publicado: (2023)

Simultaneous Manifestation of Chronic Myelomonocytic Leukemia and Multiple Myeloma during Treatment by Prednisolone and Eltrombopag for Immune-Mediated Thrombocytopenic Purpura
por: Hagihara, Masao, et al.
Publicado: (2016)

Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis
por: Meng, Fanqiao, et al.
Publicado: (2020)

Spanish Guidelines for the use of targeted deep sequencing in myelodysplastic syndromes and chronic myelomonocytic leukaemia
por: Palomo, Laura, et al.
Publicado: (2019)

Vasculitis in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia: A Report of Two Cases
por: Jacobse, Justin, et al.
Publicado: (2018)

Successful eltrombopag treatment of severe refractory thrombocytopenia in chronic myelomonocytic leukemia: Two cases reports: A CARE-compliant article
por: Gao, Yayue, et al.
Publicado: (2017)

Eltrombopag monotherapy can improve hematopoiesis in patients with low to intermediate risk-1 myelodysplastic syndrome
por: Vicente, Alana, et al.
Publicado: (2020)

TET2 mutational status affects myelodysplastic syndrome evolution to chronic myelomonocytic leukemia
por: Quang, Violaine Tran, et al.
Publicado: (2023)

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2021)

Clinical spectrum, outcome and management of immune thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Jachiet, Vincent, et al.
Publicado: (2021)

Eltrombopag in Good's Syndrome
por: Kristiansen, Håvard Anton, et al.
Publicado: (2014)

Myelodysplastic syndrome that progressed to acute myelomonocytic leukemia with eosinophilia showing peculiar chromosomal abnormality: a case report.
por: Kim, S. H., et al.
Publicado: (1999)

Utility of indium-111 platelet scintigraphy for understanding the mechanism of thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia
por: Durand, Pauline, et al.
Publicado: (2023)

Characteristics of Granulocyte‐Macrophage Colony Formation in Chronic Myelomonocytic Leukemia: A Comparative Study with Other Myelodysplastic and Myeloproliferative Disorders
por: Yuo, Akira, et al.
Publicado: (1990)

Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia
por: Helbig, Grzegorz, et al.
Publicado: (2019)

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
por: Savona, Michael R., et al.
Publicado: (2020)

Long-Term Safety and Efficacy of Eltrombopag for Advanced Myelodysplastic Syndromes or Acute Myeloid Leukemia and Severe Thrombocytopenia: Results of the ASPIRE Extension Study
por: Mittelman, Moshe, et al.
Publicado: (2023)

Prognostic significance of SETBP1 mutations in myelodysplastic syndromes, chronic myelomonocytic leukemia, and chronic neutrophilic leukemia: A meta-analysis
por: Shou, Li-Hong, et al.
Publicado: (2017)

Genomic and Epigenomic Landscape of Juvenile Myelomonocytic Leukemia
por: Fiñana, Claudia, et al.
Publicado: (2022)

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
por: Oliva, Esther Natalie, et al.
Publicado: (2023)

The Eltrombopag antitumor effect on hepatocellular carcinoma
por: KUROKAWA, TOMOHIRO, et al.
Publicado: (2015)

Multiple thrombosis during eltrombopag therapy
por: Shimazu, Yutaka, et al.
Publicado: (2021)

Exploring the Potential of Eltrombopag: Room for More?
por: Tarantini, Francesco, et al.
Publicado: (2022)

Next‐generation sequencing of baseline genetic mutations and outcomes of eltrombopag and azacitidine therapy in patients with myelodysplastic syndromes and thrombocytopenia: Data from the SUPPORT clinical trial
por: Ramos, Pedro Marques, et al.
Publicado: (2023)

Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD
por: Vilorio-Marqués, Laura, et al.
Publicado: (2022)

Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival
por: Geissler, Klaus, et al.
Publicado: (2021)

Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series
por: Martin de Frémont, Grégoire, et al.
Publicado: (2021)

Treatment of immune thrombocytopenic purpura: focus on eltrombopag
por: Rice, Lawrence
Publicado: (2009)

Eltrombopag for the treatment of aplastic anemia: current perspectives
por: Lum, Su Han, et al.
Publicado: (2016)

Eltrombopag in long‐term management of pediatric thrombocytopenia
por: Shah, Sanjay J., et al.
Publicado: (2018)

Aplastic Anemia Treated with Eltrombopag during Pregnancy
por: Suminaga, Yuri, et al.
Publicado: (2022)

Pharmacokinetic Evaluation of Eltrombopag in ITP Pediatric Patients
por: Dionisi, Marco, et al.
Publicado: (2021)

Adding eltrombopag to immunosuppression: the importance of predicting outcome
por: Tichelli, André, et al.
Publicado: (2022)

Eltrombopag directly activates BAK and induces apoptosis
por: Chen, Meng, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hoi98bu99hmel2ranjfb09q91l